The FDA has accepted the New Drug Application for UGN-103, a next-generation intravesical mitomycin formulation for recurrent low-grade non-muscle invasive bladder cancer. In the phase 3 UTOPIA trial, UGN-103 achieved a 78% complete response rate at 3 months, with 94.5% of responders remaining event-free at 6 months. A decision is expected by June 14, 2027.
The FDA has accepted the New Drug Application (NDA) for UGN-103 (mitomycin intravesical solution), a next-generation treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Developed by UroGen, UGN-103 builds on the already-approved Zusduri by incorporating a proprietary thermo-responsive gel (RTGel®) that provides sustained mitomycin exposure in the bladder and simplifies the reconstitution process for clinical use.
The NDA is backed by data from the single-arm, phase 3 UTOPIA trial, in which 99 patients (median age 71) received UGN-103 once weekly for 6 weeks. The drug demonstrated strong efficacy and a manageable safety profile, with dysuria being the most common side effect at 19%.
By the Numbers:
Why it matters: Bladder cancer is highly recurrent, making durable, easy-to-use treatment options critical. UGN-103's simplified formulation and strong early response data could offer clinicians a more practical and effective tool for managing this challenging disease.
